Gastroenterologia y hepatologia最新文献

{"title":"Colonic obstruction secondary to a phytobezoar. A rare condition.","authors":"Nerea Ruiz-Andrés, Marta Artaza-Irigaray, María Martínez-Galilea, Elvira Ubis-Rodríguez","doi":"10.1016/j.gastrohep.2026.502845","DOIUrl":"10.1016/j.gastrohep.2026.502845","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502845"},"PeriodicalIF":2.0,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lumen-apposing metal stent as palliative treatment for malignant rectal obstruction.","authors":"Estefanía Ferre Ruiz, Antonio Jesús González Sánchez, Alberto Titos García, José Manuel Aranda Narváez","doi":"10.1016/j.gastrohep.2026.502844","DOIUrl":"10.1016/j.gastrohep.2026.502844","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502844"},"PeriodicalIF":2.0,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of the vedolizumab Clinical Decision Support Tool in Crohn's disease and its association with long-term persistence: A retrospective cohort study.","authors":"Óscar Moralejo Lozano, Alberto Flores Camuñas, María Abanades Tercero, María Jesús Carrillo Ramos, Gema Gigante González de la Aleja, Lucía Ruano Díaz, Rafael Ángel Gómez Rodríguez","doi":"10.1016/j.gastrohep.2026.502842","DOIUrl":"10.1016/j.gastrohep.2026.502842","url":null,"abstract":"<p><strong>Objective: </strong>Vedolizumab is a gut-selective monoclonal antibody approved for moderate-to-severe Crohn's disease. The Clinical Decision Support Tool (CDST) is a tool designed to help predict treatment response and enable personalized therapy. This study aim to evaluate the diagnostic performance of the CDST in a real-world CD cohort and to explore its association with vedolizumab treatment persistence.</p><p><strong>Patients and methods: </strong>Retrospective, observational, single-centre study including all Crohn's disease patients treated with vedolizumab at our centre. Primary objective was to assess diagnostic accuracy of baseline CDST for clinical remission for clinical remission at weeks 26 and 52. Secondary objectives included evaluation of CDST accuracy for corticosteroid-free clinical remission, normalization of faecal calprotectin, mucosal healing, and deep remission, as well as assessment of VDZ persistence through Kaplan-Meier and Cox regression analyses.</p><p><strong>Results: </strong>Sixty-four patients were included; 34.38% had fistulizing Crohn's disease, 73.4% prior anti-TNF exposure, and 48.4% previous intestinal surgery. Baseline mean CDST was 19.36 (SD 3.81), with 62.50% classified as high-probability responders. AUCs for clinical remission were 0.57 (week 26) and 0.64 (week 52), 0.52 (w26) and 0.64 (w52) for corticosteroid-free clinical remission. VDZ was discontinued in 32.81% of patients over a mean follow-up of 2.85 years. Baseline CDST was not associated with VDZ persistence (HR 0.98 [0.88-1.09], p=0.6696).</p><p><strong>Conclusions: </strong>In this real-world CD cohort, CDST showed poor diagnostic accuracy and did not predict treatment persistence.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502842"},"PeriodicalIF":2.0,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"True left-sided gallbladder.","authors":"Gabriela Alvarado Carrillo, Marina Pérez-Flecha González, Clara Martínez Moreno, Miguel Ángel García Ureña","doi":"10.1016/j.gastrohep.2026.502843","DOIUrl":"10.1016/j.gastrohep.2026.502843","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502843"},"PeriodicalIF":2.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver tumors in anabolic steroid users: A practical approach for the gastroenterologist and hepatologist.","authors":"Enrico Fulco, Alessia Stingo, Giancarlo Orlando","doi":"10.1016/j.gastrohep.2026.502841","DOIUrl":"10.1016/j.gastrohep.2026.502841","url":null,"abstract":"<p><p>Anabolic androgenic steroids (AAS), used at supraphysiological doses, are an underrecognized cause of primary hepatocellular tumors, particularly hepatocellular adenoma (HCA) and carcinoma (HCC), typically arising in young, non-cirrhotic patients outside the usual demographic for liver cancer. This review summarizes the clinical presentation, imaging features, and molecular basis of androgen-associated hepatocellular neoplasia and provides a practical framework for recognition and management. Androgen receptor (AR) signaling drives hepatocarcinogenesis through the cell cycle-related kinase/β-catenin pathway and mTOR complex 1-mediated AR stabilization; the β-catenin-activated HCA subtype, over-represented in this setting, carries the highest risk of malignant transformation. Because serum alpha-fetoprotein is often normal and cirrhosis is typically absent, diagnosis requires a high index of clinical suspicion and a structured exposure history. We outline an approach to imaging work-up, AAS cessation, and follow-up, and discuss when referral for biopsy, resection, or specialist hepatology review is warranted.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502841"},"PeriodicalIF":2.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148759974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory bowel disease in Spain: Scientific output, collaboration and research characteristics.","authors":"Beatriz Mateos, Isabella Dotti, Javier Conde-Aranda, Ángel De Prado, Celia Escudero-Hernández, Mireia López-Siles, Josep Manyé, Carolina Serena, Leticia Abecia, Dolores Ortiz-Masia","doi":"10.1016/j.gastrohep.2026.502838","DOIUrl":"10.1016/j.gastrohep.2026.502838","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory Bowel Disease (IBD) research in Spain has expanded considerably in recent decades; however, no structured evaluation has comprehensively assessed its scientific production or its representation at major international congresses. This study aimed to provide a descriptive overview of recent Spanish contributions to clinical, translational, and basic inflammatory bowel disease research, and to analyse scientific leadership, regional distribution, methodological approaches, research topics, and gender representation.</p><p><strong>Material and methods: </strong>Publications from 2020 to 2024 were systematically retrieved from PubMed and classified according to study type, research topic, methodology, journal quartile ranking, and authorship characteristics. Accepted communications presented at the European Crohn's and Colitis Organisation congresses between 2019 and 2024 were also evaluated regarding study type, presentation format, scientific leadership, gender of the last author, and regional origin.</p><p><strong>Results: </strong>A total of 1361 Spanish scientific contributions were identified. Clinical research represented 61.3% (n=834) of publications, whereas basic and translational studies accounted for 38.7% (n=527) of the total output. 84.5% (n=1150) of publications were published in Quartile 1 or 2 journals, and 30.6% (n=291) of Quartile 1 articles appeared in top-decile journals. Scientific activity was predominantly concentrated in Catalonia and Madrid. Advanced experimental methodologies were frequently employed in basic and translational research. Across congress communications, 638 abstracts were identified, with Spain contributing 8.5-12.4% of total accepted presentations (n=80-126 abstracts annually). Women were more frequently represented in leadership roles in basic and translational research than in clinical studies.</p><p><strong>Conclusion: </strong>The current landscape of IBD research in Spain is characterised by sustained scientific activity, a broad spectrum of clinical, translational and basic research, and extensive international collaboration, despite marked regional differences in research productivity and persistent gender disparities in leadership.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502838"},"PeriodicalIF":2.0,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opportunistic screening for hepatitis B and C in Primary Care using a reflex testing system: A microelimination model.","authors":"Imma Valls, María Santos, Rosa Soriano, Montserrat Mullol, Ariadna Rando-Segura, Elena Vargas-Accarino, María Buti","doi":"10.1016/j.gastrohep.2026.502839","DOIUrl":"10.1016/j.gastrohep.2026.502839","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain a significant public health concern. Achieving the World Health Organization (WHO) elimination targets by 2030 requires more effective detection strategies than risk factor-based screening. This study evaluates an opportunistic screening program implemented in Primary Care, incorporating an automated diagnostic and referral pathway.</p><p><strong>Patients and methods: </strong>Prospective study of universal HBsAg and anti-HCV screening conducted in a Primary Care center in Barcelona. Adults requiring a blood test for any reason between February 2023 and February 2025 were included. Positive cases were directly referred to the Hepatology Department through an automated care pathway.</p><p><strong>Results: </strong>A total of 3,103 individuals were screened (41% male; mean age 51 years). The prevalence of anti-HCV positivity was 2.0%, with 0.35% having active infection; 82% of viremic patients initiated antiviral treatment. HBsAg prevalence was 0.8%, and 92% of referred cases attended specialist care; 17% initiated treatment. A higher number of risk factors was associated with anti-HCV positivity, whereas no predictors of HBsAg positivity were identified. Notably, 45% of patients with detectable HCV RNA and 44% of HBsAg-positive individuals had neither recognized risk factors nor elevated ALT levels.</p><p><strong>Conclusions: </strong>Automated opportunistic screening in Primary Care is feasible and effective, identifying HBV and HCV infections that would likely remain undetected using risk factor-based screening strategies. This integrated approach may contribute substantially to the micro-elimination of viral hepatitis.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502839"},"PeriodicalIF":2.0,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What diagnosis underlies this giant cutaneous tumor?","authors":"Diego Armando Huanay-Martínez, Carlos García-Encinas","doi":"10.1016/j.gastrohep.2026.502840","DOIUrl":"10.1016/j.gastrohep.2026.502840","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502840"},"PeriodicalIF":2.0,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rectal endometriosis mimicking rectal cancer.","authors":"Long He, Zijian Deng, Na Wei","doi":"10.1016/j.gastrohep.2026.502824","DOIUrl":"10.1016/j.gastrohep.2026.502824","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502824"},"PeriodicalIF":2.0,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 and dual GLP-1/GIP agonists: key aspects for Gastroenterology practice.","authors":"Santiago Blanco Rey, Gabriela A González, Itziar Rubio de la Plaza, Alba Sanz Prieto, Ana Fernández Lamelas, Esteban Fuentes Valenzuela","doi":"10.1016/j.gastrohep.2026.502837","DOIUrl":"10.1016/j.gastrohep.2026.502837","url":null,"abstract":"","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502837"},"PeriodicalIF":2.0,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148684397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}